If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksConcurrent Technologies Regulatory News (CNC)

Share Price Information for Concurrent Technologies (CNC)

Share Price is delayed by 15 minutes
Get Live Data
260.00    -5.00 (-1.84%)
Bid:
255.00
Ask:
265.00
Spread: 10.00 (3.922%)
Market Cap: £242.55m
CNC Live PriceLast checked at - London Stock Exchange

Intraday Concurrent Technologies Share Chart

Trading Update

20 Jan 2026 07:00

RNS Number : 5087P
Concurrent Technologies PLC
20 January 2026
 

 20 January 2026

 

 

Concurrent Technologies Plc

("Concurrent", the "Company" or the "Group")

 

Trading Update

 

Significant year-on-year growth driven by record order intake

 

Concurrent Technologies Plc (AIM: CNC), a designer and manufacturer of leading-edge computer products, systems, and mission-critical solutions used in high-performance markets by some of the world's major OEMs, provides an update on trading for the year ended 31 December 2025 ("FY25").

 

Based on its unaudited management accounts, the Company expects both revenue and profit before tax to be in line with market expectations, delivering strong double-digit growth on FY24 (FY24: revenue £40.3m and profit before tax £5.2m).1 This reflects the growing momentum across the Group's Products and Systems business units, notwithstanding delays to US Department of Defense budget approvals and the recent US government shutdown.

 

Total order intake for FY25 was at a record level of approximately £47 million (FY24: £41 million), driven by particularly strong demand from customers in Europe and Asia-Pacific, reflecting the continued strengthening of Concurrent's reputation among leading global primes. The Group ended FY25 in a solid financial position with £14.4m of cash at bank (FY24: £13.7m), with elevated year-end debtors reflecting seasonally high invoicing.

 

In September, the Company announced a $5.2 million design services contract with a major defence prime contractor. A subsequent $1.0 million contract expansion has increased the total value to $6.2 million, making it Concurrent's largest single order to date. The expanded scope includes the design and supply of Automatic Test Equipment to support the customer's in-house production and testing, highlighting the early commercial success and growth potential of Concurrent's design services offering.

 

Outlook

The Company has entered the new financial year with good momentum, underpinned by robust customer demand, record order intake and a growing pipeline of design wins expected to convert into production revenues. This progress is supported by a solid balance sheet, providing the financial flexibility to continue investing as the Group delivers on its growth strategy in the year ahead, with strategic plans in place to manage component costs through the year as necessary.

 

Miles Adcock, CEO, commented: "FY25 was another strong year for Concurrent, in which we continued to execute on our stated strategy, as planned. With our new Los Angeles facilities now fully operational and the Colchester relocation expected to complete in H1 FY26, we believe the business is entering a new phase of operational capacity. We will see prior design wins begin translating into meaningful orders, while strengthening and diversifying our portfolio of products and services to support long-term growth. I am extremely proud of what our team has achieved and am excited by the scale of opportunity ahead."

 

1 As at 19 January 2026, The Board understands that market expectations for FY2025, based on published analyst forecasts, are for revenue of £46.0m, and profit before tax of £6.2m.

 

Enquiries:

Concurrent Technologies PlcMiles Adcock - CEO

Kim Garrod - CFO

 

 

 

+44 (0)1206 752626

Alma Strategic CommunicationsHannah Campbell

Josh Royston

Will Merison

 

 

+44 (0)20 3405 0205

Cavendish Capital Markets Limited (NOMAD)Neil McDonald

Peter Lynch

+44 (0)131 220 9771

+44 (0)131 220 9772

 

About Concurrent Technologies Plc

Concurrent Technologies Plc develops and manufactures high-end embedded plug-in cards and systems for use in a wide range of high-performance, long-life cycle applications within the telecommunications, defence, security, telemetry, scientific and aerospace markets, including applications within extremely harsh environments. The processor products feature Intel® processors, including the latest generation embedded Intel® Core™ processors, Intel® Xeon® and Intel Atom™ processors. The products are designed to be compliant with industry specifications and support many of today's leading embedded operating systems. The products are sold world-wide.

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBLMLTMTJBBTF
Date   Source Headline
13th Nov 202011:58 amRNSDirector/PDMR Shareholding
5th Nov 20207:00 amRNSLaunch of high performance Advanced MC Board
21st Oct 20204:02 pmRNSTreasury Shares
20th Oct 20209:07 amRNSTreasury Shares
16th Oct 20207:00 amRNSIssue of Share Options and PDMR dealing
16th Oct 20207:00 amRNSTreasury Shares
6th Oct 20204:50 pmRNSTotal Voting Rights
11th Sep 20203:07 pmRNSDirector/PDMR Shareholding
2nd Sep 20207:00 amRNSInterim Results
21st Aug 20207:00 amRNSNotification of Interim Results
23rd Jul 202011:15 amRNSHolding(s) in Company
3rd Jul 20207:00 amRNSRetirement of Director
17th Jun 20202:33 pmRNSResult of AGM
16th Jun 20202:45 pmRNSAGM Statement
9th Jun 20205:17 pmRNSTotal Voting Rights & Director Shareholding
1st Jun 20207:00 amRNSHolding(s) in Company
29th May 20207:00 amRNSHolding(s) in Company
27th May 20204:55 pmRNSTotal Voting Rights & Director Shareholding
22nd May 20202:34 pmRNSPosting of Annual Report and Notice of AGM
22nd May 20207:00 amRNSDirector Appointment
12th May 20207:00 amRNSTotal Voting Rights
30th Apr 20206:18 pmRNSDirector/PDMR Shareholding
23rd Apr 20207:00 amRNSResults for the year ended 31 December 2019
17th Apr 20207:00 amRNSNotice of Results
26th Mar 20207:00 amRNSDirector Appointment and Results Timing Update
10th Mar 20207:00 amRNSSecond Interim Dividend
14th Feb 20206:06 pmRNSDirector/PDMR Shareholding
12th Feb 202012:18 pmRNSHolding(s) in Company
28th Jan 20207:00 amRNSProduct Announcement
24th Jan 20204:29 pmRNSHolding(s) in Company
21st Jan 20207:00 amRNSPost-Close Trading Update
7th Jan 20202:13 pmRNSHolding(s) in Company
7th Jan 20202:10 pmRNSHolding(s) in Company
6th Jan 202012:29 pmRNSHolding(s) in Company
20th Nov 201910:14 amRNSHolding(s) in Company
11th Oct 20191:45 pmRNSDirector/PDMR Shareholding
10th Sep 20197:00 amRNSInterim Results
9th Aug 20197:00 amRNSNotice of Interim Results
11th Jun 20198:45 amRNSProduct Announcement
22nd May 20194:41 pmRNSResult of AGM
21st May 20192:30 pmRNSAGM Statement
8th May 20197:00 amRNSDeath of Director
24th Apr 20197:00 amRNSDistribution of Annual Report and Accounts
4th Apr 20197:00 amRNSResults for the year ended 31 December 2018
29th Mar 20197:00 amRNSNotice of Results
14th Mar 20197:00 amRNSSecond Interim Dividend
6th Mar 20197:00 amRNSProduct Announcement
17th Jan 20192:50 pmRNSPost-Close Trading Update
14th Jan 20192:00 pmRNSLeave of Absence
8th Oct 20187:00 amRNSProduct Announcement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.